[
  {
    "ts": "2025-12-16T12:00:00+00:00",
    "headline": "Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)",
    "summary": "Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD",
    "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "57994114-386d-3307-9983-571024ec9741",
      "content": {
        "id": "57994114-386d-3307-9983-571024ec9741",
        "contentType": "STORY",
        "title": "Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)",
        "description": "",
        "summary": "Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD",
        "pubDate": "2025-12-16T12:00:00Z",
        "displayTime": "2025-12-16T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b",
          "originalWidth": 440,
          "originalHeight": 386,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Km.iDUymrS8htWjo9.aZZg--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b.cf.webp",
              "width": 440,
              "height": 386,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ND76FpkFurDCgVBykGeoxg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADAG"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T13:00:00+00:00",
    "headline": "Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace",
    "summary": "The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: I",
    "url": "https://finance.yahoo.com/news/immutep-announces-strong-operational-progress-130000779.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0f76b99b-4c80-335e-a8a4-02c945f66c10",
      "content": {
        "id": "0f76b99b-4c80-335e-a8a4-02c945f66c10",
        "contentType": "STORY",
        "title": "Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace",
        "description": "",
        "summary": "The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: I",
        "pubDate": "2025-12-16T13:00:00Z",
        "displayTime": "2025-12-16T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/cd983e6beca4b018d9b3ca144b589600",
          "originalWidth": 382,
          "originalHeight": 131,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u4trPsLT_6BovPoxYBoPLA--~B/aD0xMzE7dz0zODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cd983e6beca4b018d9b3ca144b589600.cf.webp",
              "width": 382,
              "height": 131,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p_wD857bCxFbkXu3hRgrgA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cd983e6beca4b018d9b3ca144b589600.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immutep-announces-strong-operational-progress-130000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immutep-announces-strong-operational-progress-130000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IMMP"
            },
            {
              "symbol": "PRRUF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T23:03:41+00:00",
    "headline": "Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast",
    "summary": "Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.",
    "url": "https://www.fool.com/coverage/stock-market-today/2025/12/16/stock-market-today-dec-16-pfizer-falls-after-cutting-2025-revenue-forecast/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "82287df5-21cd-3774-b7ff-3f7da26379c6",
      "content": {
        "id": "82287df5-21cd-3774-b7ff-3f7da26379c6",
        "contentType": "STORY",
        "title": "Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast",
        "description": "",
        "summary": "Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.",
        "pubDate": "2025-12-16T23:03:41Z",
        "displayTime": "2025-12-16T23:03:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b2266bf4e5454ef1a196b91a1f82ea1a",
          "originalWidth": 1401,
          "originalHeight": 1251,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M2MzQpciI2zqH3bt4p6Z4Q--~B/aD0xMjUxO3c9MTQwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/b2266bf4e5454ef1a196b91a1f82ea1a.cf.webp",
              "width": 1401,
              "height": 1251,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a1lMjbUUZQTJ4b4evRUbQw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b2266bf4e5454ef1a196b91a1f82ea1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/stock-market-today/2025/12/16/stock-market-today-dec-16-pfizer-falls-after-cutting-2025-revenue-forecast/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-dec-16-230341600.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T21:00:02+00:00",
    "headline": "Sector Update: Health Care Stocks Retreat Late Afternoon",
    "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-retreat-210002940.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "9cbe38e6-e1bd-3d3d-9342-195441e8b6be",
      "content": {
        "id": "9cbe38e6-e1bd-3d3d-9342-195441e8b6be",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Retreat Late Afternoon",
        "description": "",
        "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and",
        "pubDate": "2025-12-16T21:00:02Z",
        "displayTime": "2025-12-16T21:00:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-retreat-210002940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-retreat-210002940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "ADAG"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "ABVX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T19:34:30+00:00",
    "headline": "Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space, the firm […]",
    "url": "https://finance.yahoo.com/news/merck-mrk-price-target-lifted-193430159.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "b93c8b2a-b0c9-3938-a3e6-bb85e3f098f7",
      "content": {
        "id": "b93c8b2a-b0c9-3938-a3e6-bb85e3f098f7",
        "contentType": "STORY",
        "title": "Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space, the firm […]",
        "pubDate": "2025-12-16T19:34:30Z",
        "displayTime": "2025-12-16T19:34:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a8ba76827d6ac52cc8d6c3f02ee33494",
          "originalWidth": 1920,
          "originalHeight": 1440,
          "caption": "Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cLbYCdtOoj120Uelo9cGKA--~B/aD0xNDQwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/a8ba76827d6ac52cc8d6c3f02ee33494.cf.webp",
              "width": 1920,
              "height": 1440,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9Erk37dyXrImJWmhBWRSQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a8ba76827d6ac52cc8d6c3f02ee33494.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-price-target-lifted-193430159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-price-target-lifted-193430159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T17:27:00+00:00",
    "headline": "Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?",
    "summary": "Each company has a bullish case, but three stand out as great long-term buys.",
    "url": "https://www.fool.com/investing/2025/12/16/should-you-buy-the-5-highest-paying-dividend-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1e01f519-1e92-3c2f-bde5-f94ad29c7c47",
      "content": {
        "id": "1e01f519-1e92-3c2f-bde5-f94ad29c7c47",
        "contentType": "STORY",
        "title": "Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?",
        "description": "",
        "summary": "Each company has a bullish case, but three stand out as great long-term buys.",
        "pubDate": "2025-12-16T17:27:00Z",
        "displayTime": "2025-12-16T17:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/caea9d2a0a6cfd70e8c4b9da0074813c",
          "originalWidth": 720,
          "originalHeight": 507,
          "caption": "VZ Dividend Yield Chart",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FGSewYYXj4lAGShsZwyIQQ--~B/aD01MDc7dz03MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/caea9d2a0a6cfd70e8c4b9da0074813c.cf.webp",
              "width": 720,
              "height": 507,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SwXn.ASjOSpTfq8ysmBxEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/caea9d2a0a6cfd70e8c4b9da0074813c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/16/should-you-buy-the-5-highest-paying-dividend-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-5-highest-paying-dividend-172700638.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "VZ"
            },
            {
              "symbol": "KO"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "BA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T14:44:00+00:00",
    "headline": "Eli Lilly or Merck: Where Should Investors Put Their Money?",
    "summary": "LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.",
    "url": "https://finance.yahoo.com/news/eli-lilly-merck-where-investors-144400604.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9e7fdf89-8ae6-3f5b-97b7-50b01321fd14",
      "content": {
        "id": "9e7fdf89-8ae6-3f5b-97b7-50b01321fd14",
        "contentType": "STORY",
        "title": "Eli Lilly or Merck: Where Should Investors Put Their Money?",
        "description": "",
        "summary": "LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.",
        "pubDate": "2025-12-16T14:44:00Z",
        "displayTime": "2025-12-16T14:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-merck-where-investors-144400604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-merck-where-investors-144400604.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T14:06:46+00:00",
    "headline": "Is Merck Still Attractive After Oncology Pipeline Progress And Strong Five Year Share Price Gains",
    "summary": "If you are wondering whether Merck is still attractively priced today, or if the market has already priced in much of the potential upside, this is a good place to dig into what the numbers may indicate about its value. Merck’s share price is around $100.26, with gains of 1.3% over the last week, 7.9% over the last month, and 55.4% over five years. These moves highlight both resilience in the stock and changing expectations around its long term growth and risk profile. Recent headlines have...",
    "url": "https://finance.yahoo.com/news/merck-still-attractive-oncology-pipeline-140646780.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dd666474-0373-3405-b9a7-d1fcae3356a1",
      "content": {
        "id": "dd666474-0373-3405-b9a7-d1fcae3356a1",
        "contentType": "STORY",
        "title": "Is Merck Still Attractive After Oncology Pipeline Progress And Strong Five Year Share Price Gains",
        "description": "",
        "summary": "If you are wondering whether Merck is still attractively priced today, or if the market has already priced in much of the potential upside, this is a good place to dig into what the numbers may indicate about its value. Merck’s share price is around $100.26, with gains of 1.3% over the last week, 7.9% over the last month, and 55.4% over five years. These moves highlight both resilience in the stock and changing expectations around its long term growth and risk profile. Recent headlines have...",
        "pubDate": "2025-12-16T14:06:46Z",
        "displayTime": "2025-12-16T14:06:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-still-attractive-oncology-pipeline-140646780.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-still-attractive-oncology-pipeline-140646780.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]